MDLN is the ticker symbol for Medline Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks MDLN with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is MDLN a good stock to buy?

13F Pro's AI ranking engine scores MDLN at 62.5/100, ranked #710 of 2,960 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for MDLN is available at https://13fpro.ai/company/MDLN. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source MDLN data?

All Medline Inc. fundamentals and ownership data come directly from SEC EDGAR. Medline Inc. files with the SEC under CIK 2046386. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Medline Inc.(MDLN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-27.

Medline Inc. (MDLN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDLN at 62.5/100 on a 32-signal composite quality model, placing it at rank #710 of 2,960 stocks — the top 25% of the AI-ranked universe. MDLN scores in the top quartile across institutional flow (97.8), revenue scale (94.8), earnings quality (89.1). Based on the latest XBRL financial filings (Q2 2026), Medline Inc. reports quarterly revenue of $7.7B, net income of $139.0M, an operating margin of 5.1%. Top institutional holders of MDLN by reported 13-F value include Carlyle Group, H&F Corporate Investors X, Ltd., FMR, based on the most recent SEC filings. MDLN trades on the Nasdaq exchange and files with the SEC under CIK 2046386. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medline Inc. directly from SEC EDGAR.

AI Quality Score

62.5/100

AI Rank

#710

Revenue

$7.7B

Net Income

$139.0M

Free Cash Flow

$604.0M

Operating Margin

5.1%

MDLN key financials by period

Medline Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$28.4B	$1.2B	7.8%
FY 2024	10-K	$25.5B	—	8.4%
FY 2023	10-K	$23.2B	—	5.4%

Institutions holding MDLN

Institutional investors reporting a position in Medline Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
Carlyle Group	187,083,713	$7.4B	2026-06-30
H&F Corporate Investors X, Ltd.	70,874,326	$2.8B	2026-06-30
FMR	46,963,203	$1.9B	2026-06-30
Capital Research Global Investors	39,963,790	$1.6B	2026-06-30
Invesco Ltd.	38,346,937	$1.5B	2026-06-30
BlackRock	26,393,587	$1.0B	2026-06-30
MORGAN STANLEY	21,605,662	$852.1M	2026-06-30
LONE PINE CAPITAL	20,968,367	$827.0M	2026-06-30
MASSACHUSETTS FINANCIAL SERVICES	19,888,806	$787.1M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	17,816,057	$702.7M	2026-06-30

SEC EDGAR: CIK 2046386 →

Medline Inc.

MDLN

NasdaqLarge CapHealthcare

13F Pro Quality Score

62.5/100

Rank #710 of 2,960 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

58.8/100

Profitability

41.6/100

Balance Sheet

51.1/100

Earnings Quality

89.1/100

Free Cash Flow

44.1/100

Institutional Flow

97.8/100

Revenue Scale

94.8/100

Dilution Risk

83.5/100

Price Chart

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

What's Driving MDLN's Business? Latest 10-Q Breakdown

31/31 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 27, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales grew 11.6% YoY to $7.7B, but net income fell 58.3% YoY to $139M as a $336M fire at the Tracy, California distribution center and a post-IPO effective tax rate jump to 40.9% offset revenue growth.

Biggest Revenue Drivers

Supply Chain Solutions$4,145M+16.3% YoY

Driven by volume growth in Prime Vendor sales, including new relationship signings and growth with existing customers

Medline Brand$3,540M+6.6% YoY

Driven by volume growth in Prime Vendor sales, partially offset by $89M of customer repayments associated with tariff refunds

Biggest Revenue Drivers

Total revenue: $7.7B+11.6% YoY

Supply Chain Solutions$4,145M+16.3% YoY

Driven by volume growth in Prime Vendor sales, including new relationship signings and growth with existing customers

Medline Brand$3,540M+6.6% YoY

Driven by volume growth in Prime Vendor sales, partially offset by $89M of customer repayments associated with tariff refunds

Within Medline Brand

Front Line Care$1,652M+3.8% YoY

Volume growth including exam gloves and personal care products, partially offset by tariff refund customer repayments

Surgical Solutions$1,640M+8.7% YoY

Volume growth in kitting and operating room products, partially offset by tariff refund customer repayments

Laboratory and Diagnostics$248M+12.2% YoY

Volume growth in laboratory products

Largest Expense Items

Cost of goods sold$5,470M+9.8% YoY

Growth in net sales and higher import costs due to tariffs, partially offset by tariff refunds

Selling, general and administrative expenses$1,295M+20.7% YoY

$156M higher compensation and benefits from headcount investment (incl. $15M one-time IPO bonuses) and $24M higher distribution/outbound freight expense

Other operating expenses$348M+334M YoY (NM)

Primarily driven by the fire at the Tracy, California distribution center

Margins: Gross margin expanded to 28.8% from 27.7% on net tariff refunds, partially offset by higher import costs from tariffs. Operating income still fell 38.5% YoY to $395M as the Tracy fire loss and higher SG&A outweighed gross profit gains.

Watch Items from the Filing

A June 11, 2026 fire destroyed the Tracy, California distribution center, causing $336M of estimated losses ($204M inventory, $116M fixed assets, $16M other) with no insurance recoveries yet recorded.
Effective income tax rate jumped to 40.92% from 7.16% YoY, driven by the post-IPO Reorganization subjecting more income to corporate-level U.S. federal and state taxes.
Three unresolved FDA warning letters cover Quality Management System and cGMP compliance at the Northfield, Glens Falls, and Waukegan facilities, with remediation expected to raise costs in H2 FY2026.
Tariffs had a ~$110M net negative impact on pretax income in Q2, while the company expects ~$507M in total IEEPA tariff refund claims following a Supreme Court ruling invalidating the tariffs.
Supply Chain Solutions Segment Adjusted EBITDA margin fell to 4.9% from 5.6% YoY due to customer mix from new Prime Vendor signings at lower margins.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →